Roche and NeoImmuneTech to test combination therapy in skin cancers
Executive Summary
Roche agreed to conduct a combination study of its Tecentriq (atezolizumab) with NeoImmuneTech Inc.’s HyLeukin-7 (IL-7-hyFc) in three high-risk skin cancers: melanoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice